Praxis Precision Medicines, Inc. (PRAX)

NASDAQ: PRAX · Real-Time Price · USD
162.71
+105.36 (183.71%)
At close: Oct 16, 2025, 4:00 PM EDT
171.50
+8.79 (5.40%)
After-hours: Oct 16, 2025, 7:59 PM EDT
183.71%
Market Cap3.42B
Revenue (ttm)7.77M
Net Income (ttm)-251.01M
Shares Out 21.05M
EPS (ttm)-12.33
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume13,742,246
Open158.29
Previous Close57.35
Day's Range156.41 - 205.89
52-Week Range26.70 - 205.89
Beta2.64
AnalystsStrong Buy
Price Target127.55 (-21.61%)
Earnings DateNov 5, 2025

About PRAX

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company’s platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical tr... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 16, 2020
Employees 116
Stock Exchange NASDAQ
Ticker Symbol PRAX
Full Company Profile

Financial Performance

In 2024, PRAX's revenue was $8.55 million, an increase of 249.53% compared to the previous year's $2.45 million. Losses were -$182.82 million, 48.3% more than in 2023.

Financial Statements

Analyst Summary

According to 11 analysts, the average rating for PRAX stock is "Strong Buy." The 12-month stock price target is $127.55, which is a decrease of -21.61% from the latest price.

Price Target
$127.55
(-21.61% downside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

1 hour ago - GlobeNewsWire

Praxis Precision Medicines, Inc. (PRAX) Discusses Essential3 Topline Results and Next Steps in Essential Tremor Program Transcript

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Discusses Essential3 Topline Results and Next Steps in Essential Tremor Program October 16, 2025 8:00 AM EDT Company Participants Marcio Souza - Preside...

4 hours ago - Seeking Alpha

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

9 hours ago - GlobeNewsWire

Praxis Precision's tremor-drug trial succeeds where others have failed. The stock is skyrocketing.

Shares of Praxis Precision Medicines have hit their highest intraday level since March 2022.

11 hours ago - Market Watch

What's fueling PRAX stock's jaw-dropping 235% surge on Thursday?

Praxis Precision Medicines (NASDAQ: PRAX stock) saw a skyrocketing 235% rally on Thursday after announcing positive topline results from two pivotal Phase 3 studies of ulixacaltamide for essential tre...

13 hours ago - Invezz

Praxis Precision Medicines' movement disorder drug shows promise in trials

Praxis Precision Medicines said on Thursday its experimental drug for movement disorder helped improve daily functioning in patients in two late-stage trials.

18 hours ago - Reuters

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

14 days ago - GlobeNewsWire

ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update

MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, tod...

17 days ago - Business Wire

Praxis Precision Medicines to Participate in September Investor Conferences

BOSTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ther...

6 weeks ago - GlobeNewsWire

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo...

6 weeks ago - GlobeNewsWire

Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline

BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) d...

7 weeks ago - GlobeNewsWire

PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES , Aug. 14, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Praxis Precision Med...

2 months ago - PRNewsWire

Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses

2 months ago - GlobeNewsWire

Praxis Precision Medicines, Inc. (PRAX) Q2 2025 Earnings Call Transcript

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants a - Corporate Participant Marcio Silva De'Souza - President, CEO & Direc...

2 months ago - Seeking Alpha

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results

RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in seizure frequency from baseline, with 22% at 100% seizure reduction in las...

2 months ago - GlobeNewsWire

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies

The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs)

3 months ago - GlobeNewsWire

Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside

Chardan Research initiated coverage on Praxis Precision Medicines, Inc. PRAX on Wednesday, citing the potential of its epilepsy franchise.

5 months ago - Benzinga

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

On track for six major study readouts across four programs over the next 12 months Ready to initiate pivotal studies in two developmental and epileptic encephalopathy (DEE) programs in mid-year 2025: ...

5 months ago - GlobeNewsWire

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies f...

6 months ago - GlobeNewsWire

Praxis Precision Medicines to Participate in Upcoming April Conferences

BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies f...

7 months ago - GlobeNewsWire

Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)

Ulixacaltamide's Phase 3 study was recommended to stop for futility, significantly lowering its chances of success in essential tremor. Investor focus shifts to the epilepsy pipeline, led by vormatrig...

8 months ago - Seeking Alpha

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...

8 months ago - GlobeNewsWire

Praxis Precision Medicines to Present at Two February Investor Conferences

BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo...

9 months ago - GlobeNewsWire

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028

9 months ago - GlobeNewsWire

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those ...

10 months ago - GlobeNewsWire